The FDA approves the treatment of kidney disease

On Tuesday, Food and Drug Administration approved OZMPIC to reduce the risk of sedate complications in people who have both type 2 diabetes and chronic kidney disease.

Type 2 diabetes is the main cause of chronic kidney disease, which affects more than one in seven adults in the USA. Drugs may reduce the chance that patients with both conditions deteriorate in kidney disease, kidney failure and death due to cardiovascular problems.

“Over the past 20 years, it was an area where researchers have tried very much, but they have not provided much,” said Dr. Stephen Gough, senior vice president of global medical matters at Novo Nordisk, a company that makes Ozempic. “Having something fresh is really invigorating and offers patients,” he said.

Ozmpic is already approved for the treatment of type 2 diabetes and lowering the risk of sedate cardiovascular events in adults with diabetes and the history of heart disease. The FDA based its decision on the extension of approved applications of OZEMPIC in studies showing that people with type 2 diabetes and chronic kidney disease that took the medicine had a 24 -percentage less likely to complicate, such as the requirement of dialysis or transplant placebo. They also had slower renal decline indicators and were less likely to die because of problems with cardiovascular system.

“The more we can delay the drop in kidney function, the better,” said Dr. Melanie Hoenig, a nephrologist from Beth Israel Deaconess Medical Center in Boston. Dr. Hoenig said that she is already rewriting to some patients.

Doctors have long expressed frustration because of how few treatment options are. Many patients take medicines to reduce blood pressure, blood sugar and cholesterol, which are usually increased in people with chronic kidney disease. Patients sometimes also take drugs to relieve swelling that occur when the kidneys cannot properly filter fluid, as well as drugs for managing iron, calcium and vitamin D.

Doctors also routinely encourage lifestyle changes, including diet and exercise modification, partly because they can facilitate manage type 2 diabetes. High blood sugar can damage the blood vessels in the kidneys, preventing them from filtering blood waste. Dr. Gought said that about 40 percent of people with type 2 diabetes would develop chronic kidney disease.

It is not clear how ozempic can bring renal benefits outside of diabetes management. Scientists theoretized that ozempic reduces inflammation throughout the body, including in the kidneys. This can facilitate explain why drugs and similar drugs turn out to be so useful in a number of chronic states, including cardiovascular problems. Drugs have side effects, most often gastrointestinal problems such as nausea, vomiting and abdominal pain.

Approval means that doctors will now be able to prescribe the medicine especially for chronic kidney disease in diabetes patients, and insurance companies will have more pressure to cover OZMPIC.

Because more and more people are looking for Ozchpik, Novo Nordisk tried to keep up with demand. . FDA lists Semaglutide, a compound in Ozmpic and a drug for slimming Wegova, which is currently missing.

“Unfortunately, many people can’t get it,” said Dr. Hoenig. “But if they can work for them, and they can tolerate it, it’s wonderful to have more tools.”